Redeye has updated its estimates and valuation following Kontigo Care’s Q4’23 report. While we are encouraged by the all-time high in Monthly Recurring Revenue (MRR), we acknowledge the challenges anticipated for growth in 2024 due to reduced municipal budgets. However, we remain optimistic about the upcoming launch of Previct Drugs in 2024, which is expected to open doors to new customer segments. Our new Base case valuation is SEK6.5 (previously 8.0) per share.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Kontigo Care - Investing for growth

© Modular Finance, source Nordic Press Releases